Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma
Melanoma accounts for over 85% of all skin cancer deaths. Current therapies including drugs targeting BRAF and MEK significantly improve the prognosis of metastatic melanoma patients, yet innate or acquired resistance challenges long-term responses. We have shown previously that fatty acid beta-oxidation (FAO) is up-regulated during the acquisition of BRAF-inhibitor (BRAFi) resistance and that the FDA approved drug ranolazine, by targeting FAO attenuates the development of acquired resistance. However, how ranolazine-induced metabolic rewiring increases cell death is unclear. Here we identify ranolazine as a ferroptosis inducer in BRAFi-resistant melanoma, in which FAO serves as a ferroptosis surveillance mechanism. Accordingly, in progressed tumours of BRAFi treated patients up-regulation of FAO regulators correlates with increased expression of ferroptosis markers. BRAFi resistant cells are heavily poised for execution of ferroptosis; they display reduced glutathione levels, higher levels of long-chain polyunsaturated fatty acid (PUFA) membrane-incorporation, and increased membrane-resident phospholipid oxidation, all of which is amplified by ranolazine. Counteracting ranolazine action is MBOAT1/2 mediated phospholipid remodelling, which initiates reduced PUFA membrane-incorporation as ferroptosis surveillance mechanism. We show that the androgen receptor (AR), which is a determinant of BRAFi resistance, controls MBOAT1/2 expression, thereby contributing to ferroptosis resistance. In BRAFi resistant tumours and cell lines, we confirm AR upregulation predominantly in the MITFlow/AXLhigh undifferentiated/neural-crest like state, but it also occurs in the MITFhigh/AXLlow differentiated melanocytic state. The AR antagonist enzalutamide sensitises AR expressing melanoma cells to RSL3 and erastin independent of phenotype state, but in FAOhigh BRAFi relapsed tumours AR up-regulation correlates with the undifferentiated/neural-crest like (UD/NC) state, and enzalutamide synergises with ranolazine in ferroptosis-induction in UD/NC cells. Thus, therapeutically combining ranolazine with the AR inhibitor enzalutamide to induce ferroptosis can circumvent dedifferentiation related BRAFi resistance and could increase therapeutic activity and long-term efficacy., I.A. and P.A. acknowledge funding from the Ministry of Economy and Competitiveness (Institute of Health Carlos III-ISCIII; refs. PI19/00645 to I.A., PI16-01911 to I.A., CPII20/00011 to I.A., CD21/00137 to P.A. I.A. and A.V.L are also funded by Departamento de Salud del Gobierno de Navarra, Spain (refs. G°Na 71/17 and GN2024-54). I.A. and M.R.M. acknowledge funding from The Spanish Association against Cancer (AECC; PRYES223349AROZ). M.R.M. was funded by a PhD studentship from the Department of Industry of the Government of Navarra, Spain, by the Grupo Español Multidisciplinar de Melanoma and the Asociación Española Contra el Cáncer. P.A. was funded by a Sara Borrell contract from ISC-III. The University of Colorado School of Medicine Metabolomics Core is supported in part by the University of Colorado Cancer Centre award from the National Cancer Institute P30CA046934.